We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Plans to Require REMS for Some Pain Products
FDA Plans to Require REMS for Some Pain Products
February 17, 2009
The FDA has informed several brand- and generic-drug makers that it will require risk evaluation and mitigation strategies (REMS) to help prevent abuse of opioid pain products such as transdermal patches.